News Releases

26 Jan '21
— Based upon successful completion of the GAIN Trial’s interim analysis, pipeline expansion announced for 2021 — Atuzaginstat to be studied in the PEAK trial, a new Phase 2 study for Parkinson’s disease — COR588, a novel lysine gingipain inhibitor, on track to enter the clinic in Q3 2021 — Top-line